FMP
Immunovant, Inc.
IMVT
NASDAQ
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
25.86 USD
0.2 (0.773%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Peter Salzmann M.B.A., M.D.
sector
Healthcare
industry
Biotechnology
website
https://immunovant.comexchange
NASDAQ
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
CIK
0001764013
ISIN
US45258J1025
CUSIP
45258J102
Address
320 West 37th Street
Phone
917 580 3099
Country
US
Employee
207
IPO Date
Jun 21, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
IMVT Financial Summary
CIK
0001764013
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45258J102
ISIN
US45258J1025
Country
US
Price
25.86
Beta
0.71
Volume Avg.
811.76k
Market Cap
3.8B
Shares
-
52-Week
24.61-45.58
DCF
4.6
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-11.7
P/B
-
Website
https://immunovant.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IMVT News
It looks like there's no news available.
